The Class I MAGE proteins include the MAGE-A, MAGE-B, and MAGE-C antigens, which are normally expressed only in male germ cells but may be aberrantly expressed in melanomas and other tumors. It is known that MAGE gene expression is epigenetically repressed by promoter region methylation in most cells but factors controlling MAGE gene promoter methylation have not been identified. Using transcript microarray analysis and immunoblotting we found that MAGE-A and MAGE-C mRNA and protein are selectively downregulated by pharmacologic inhibition of KIT in KIT-dependent mast cell lines. Methylation-specific polymerase chain reaction studies showed that the MAGE-A3 and MAGE-C2 gene promoter regions were de-methylated in the presence of activated KIT but became methylated on inhibition of KIT, consistent with the downregulation of mRNA and protein. This is early evidence of a tyrosine kinase affecting MAGE gene promoter region methylation and expression, and represents early evidence of a tyrosine kinase in the epigenetic control of gene expression. MAGE proteins suppress apoptosis and promote tumor survival, and are novel targets for functional manipulation and immunotherapy. Understanding the factors controlling MAGE gene expression may allow more effective therapeutic strategies targeting MAGE antigens.
INTRODUCTION
The MAGE-A, MAGE-B, and MAGE-C families comprise the Class I MAGE genes (Simpson et al. , 2005) . Class I MAGE genes are normally expressed only in developing cells of the spermatogenic series but are of general interest because they may be aberrantly expressed in melanomas and other malignancies (Knuth et al., 1989; Jungbluth et al., 2000) . It has been established that MAGE gene expression is suppressed by methylation of critical CpG dinucleotide islands in the MAGE gene promoter regions (De Smet et al., 1999; Sigalotti et al., 2004) , but other factors besides promoter region hypomethylation are necessary for expression (Karpf et al., 2004) . Unlike most genes, the promoter regions of Class I MAGE genes are normally methylated and MAGE gene expression is repressed in all cells except male germ cells. It is interesting that these cells also express the KIT tryosine kinase (Strohmeyer et al., 1995) .
Recently, while studying downstream signaling pathways of the KIT tyrosine kinase, we noted that KIT-dependent mast cell lines express Class I MAGE genes, and that their expression suppresses apoptosis (Yang et al., 2007) . Here, we show that inhibition of the KIT kinase in these cells results in downregulation of MAGE gene mRNA, methylation of MAGE gene promoters, and suppression of MAGE protein expression. These findings identify a novel mechanism of KIT signal transduction and, to our knowledge, represent the first demonstration of epigenetic control of a gene by a tyrosine kinase.
RESULTS

Inhibition of KIT downregulates MAGE gene expression
Human malignant mast cell line (HMC1) expresses mutated, constitutively active KIT that drives cell proliferation and prevents apoptosis (Ma et al., 2002) . HMC1.1 and HMC1.2 are two subclones of HMC1 that express KIT mutations, which differ in their sensitivity to a clinically useful KIT tyrosine kinase inhibitor called ''Imatinib.'' HMC1.1 expresses KIT with a codon 560 substitution that disrupts an intracellular juxtamembrane auto inhibitory region, thereby activating the KIT kinase without changing the structure of the kinase enzymatic site. In contrast, HMC1.2 expresses KIT with a codon 816 mutation that alters the activation loop of the kinase enzymatic site. The mutated KIT expressed by HMC1.1 is sensitive to inhibitors of wild-type kinases like Imatinib, whereas the mutated KIT expressed by HMC1.2 is resistant to Imatinib (Figure 1 ).
Class I MAGE genes are coordinately downregulated during KIT-dependent apoptosis
To identify genes involved in KIT regulation of growth and survival, we used mRNA array analysis to compare gene expression levels in HMC1.1 and HMC1.2 before and after treatment with Imatinib. As we expected, we found that treatment of the Imatinib-sensitive HMC1.1 cell line induced significant changes in expression of a large number of genes (499), most of which are associated with cell growth and maintenance; there were changes in the expression of genes controlling growth factor response, signal transduction, and phosphate metabolism (Table 1) . Treatment of HMC1.2, which expresses mutation-activated KIT that is resistant to Imatinib, showed almost no effect following treatment with Imatinib, indicating remarkable specificity of the drug in these cells. No genes changed more than twofold and only 25 of 22,000 showed changes between one-and twofold, compared with 499 genes in this range for the Imatinib-sensitive HMC1.1 cell line. Furthermore, none of the 25 genes in the 1-2-fold range in HMC1.2 match those that change in HMC1.1, indicating that they are unlikely to represent an effect of the drug but more likely represent chance effects seen when significance tests are applied to 22,000 genes, despite using the Bonferroni correction. Subtracting the ''noise'' of 25 genes in HMC1.2 from the 499 genes in HMC1.1 still leaves 474 genes with significant change in the Imatinib-sensitive HMC1.1 line.
In reviewing the microarray data, we had noticed that both mast cell lines expressed transcripts for multiple Class I MAGE family proteins, a novel observation (Yang et al., 2007) . Interestingly, we also noted that expression of many MAGE family mRNAs was downregulated in the sensitive HMC1.1 line as early as 4 hours after induction of apoptosis by Imatinib, but MAGE mRNA expression was not changed by Imatinib in the resistant HMC1.2 cell line ( Table 2) . Immunoblotting of HMC1.1 and HMC1.2 whole cell lysates from before and at 12 and 24 hours after treatment with Imatinib showed regulation of MAGE family proteins in HMC1.1 but not HMC1.2 cells, confirming the physiologic significance of the mRNA array data (Figure 2 ). Note that the array analysis experiments were designed to detect the earliest changes in gene expression after KIT inhibition and the decreases in MAGE mRNA levels in the early stages of response to Imatinib are small but statistically significant. The biologic relevance of these changes, however, is confirmed by the dramatic drop in protein at the later time points.
KIT inactivation causes MAGE-A3 and MAGE-C2 promoter region methylation
As MAGE-A3 is the MAGE antigen most commonly expressed in human malignancies, we focused on it as representative of the MAGE-A family proteins. We also studied MAGE-C2, as it was the only other Class I MAGE gene with significant expression in HMC1.1 cells (Table 2 and Figure 2 ). It is known that hypermethylation of specific promoter region CpG dinucleotide islands suppresses expression of MAGE-A3 and MAGE-C2 (De Smet et al., 1999; Furuta et al., 2004; Wischnewski et al., 2006) , so we used methylation-specific polymerase chain reaction to determine the effects of KIT inhibition on CpG island methylation in these promoter regions. The first row of Figure 3 shows that the MAGE-A3 promoter region is normally hypomethylated in both the HMC1.1 and HMC1.2 cell lines, and that inhibition of KIT by In HMC1.1 cells, 499 genes showed 41-fold change in median expression and 17 genes showed 42-fold change. In HMC1.2 cells, only 25 genes showed 41-fold change and none showed 42-fold change. The genes listed were classified according to overlapping categories including molecular function and biological processes, and some genes are included in more than one category, so the total numbers are not the actual numbers of changed genes. *Indicates Pp0.05 compared with untreated cells.
Imatinib in HMC1.1 causes methylation of the MAGE-A3 promoter. In contrast, there is no change in MAGE-A3 promoter region methylation in HMC1.2, which expresses activated KIT that is resistant to Imatinib. The second row of Figure 3 shows similar results with the MAGE-C2 promoter except that inhibition of KIT results in a heterogeneous pattern of methylation in HMC1.1, so that both methylated and unmethylated MAGE-C2 promoter region DNA are detected in Imatinib-treated HMC1.1 cells. This last result is not surprising given that heterogeneous patterns of MAGE promoter region methylation have previously been observed in melanoma cell lines (Furuta et al., 2004; Sigalotti et al., 2004) . In HMC1.1 cells, this pattern correlates with a significant decrease in MAGE-C2 mRNA and protein ( Figure 2 ). In contrast, treatment with Imatinib has no significant effect on MAGE-C2 promoter methylation in the Imatinib-resistant HMC1.2 cell line, indicating that activated KIT can maintain MAGE promoter regions in a hypomethylated state, thereby contributing to control of MAGE protein expression. This experiment serves as an important control for our results with the HMC1.1 cell line because although it appears that additional factors downstream of promoter methylation affect MAGE-C2 mRNA and protein expression in HMC1.2 cells, our observations with HMC1.2 cells show that the changes in promoter region methylation are only seen when KIT is affected and are not a non-specific effect of Imatinib.
DISCUSSION
Understanding mechanisms controlling MAGE gene expression is of interest because MAGE proteins may contribute to the development of melanomas and other malignancies, and to their resistance to cytotoxic agents (Dhodapkar et al., 2003; Duan et al., 2003; Monte et al., 2006; Yang et al., 2007) . In addition, because MAGE protein expression is normally limited to developing male germ cells, MAGE proteins have served as tumor-specific antigens in a number of immunotherapeutic strategies including some involving manipulation of MAGE gene expression (De Smet et al., 1999; Park et al., 1999; Coulie et al., 2002) . A number of studies have identified expression of the Class I MAGE proteins A1, A3, and A4 in prenatal human gonocytes, prespermatogonia, and spermatocytes (Takahashi et al., 1995; Gaskell et al., 2004) and expression of MAGE-C proteins has been shown in adult testicular germ cells (Jungbluth et al., 2002) . The basis for this tissue-specific Immunoblotting shows MAGE-A and MAGE-C proteins are downregulated in HMC1.1 cells at 12 and 24 hours after induction of apoptosis by Imatinib, but not downregulated in the Imatinib-resistant HMC1.2 cell line. Note that no significant expression of MAGE-B protein is identified. Note also that the HMC1.2 cell line does not express detectable MAGE-C2 protein, in agreement with the very low levels of MAGE-C2 mRNA seen in this cell line. regulation has not been previously established, but our data suggest that expression of activated KIT may allow MAGE gene expression by suppressing the methylation of MAGE promoter regions that is normally found in all tissues besides the testes. In support of this hypothesis is the fact that all cells of the spermatogenic series in adult testes express both KIT and MAGE proteins up through meiosis (Sandlow et al., 1997; Yin et al., 1998; Jungbluth et al., 2000 Jungbluth et al., , 2002 . Thus, expression of Class I MAGE proteins is temporally and spatially associated with expression of KIT in testes, supporting the hypothesis that KIT activation may contribute to normal tissue-specific regulation of MAGE proteins. A normal function for MAGE proteins is suggested by the facts that expression of select MAGE proteins prevents p53-mediated apoptosis (Monte et al., 2006; Yang et al., submitted) and that p53 expression is critical for normal spermatogenesis (Yin et al., 1998; Monte et al., 2006; Yang et al., 2007) . For instance, p53 À/À mice show decreased germ cell apoptosis, an increased percentage of morphologically abnormal sperm, and reduced fertility, suggesting that p53-dependent cellular proofreading maintains the integrity of male germ cells during spermatogenesis. Loss of PI3-K binding by the KIT mutant Y719F results in a 90% reduction in AKT activation, but mice homozygous for this mutant have normal mast cells and melanocytes (Blume-Jensen et al., 2000) , probably because of redundancy of KIT-dependent pathways that activate proliferation. However, male but not female kit Y719F homozygotes are sterile owing to extensive apoptosis occurring at the spermatogonial stem cell level, indicating a failure of the mutant KIT to suppress apoptosis. Interestingly, male mice homozygous for the kit WÀv loss of function mutation have decreased germ cell viability and are infertile, but this defect is rescued in double-mutant p53 À/À kit WÀv/WÀv mice, indicating that KIT may normally protect developing male germ cells by suppressing a p53-dependent apoptotic pathway (Jordan et al., 1999) . KIT also appears to be relevant to human fertility as decreased KIT expression is seen in testes of subfertile adult humans, and is associated with increased apoptosis in spermatocytes (Feng et al., 1999) . We have recently shown that MAGE proteins suppress p53 expression and apoptosis (Yang et al., 2007; Yang et al., submitted) , and we speculate that the normal function of MAGE genes may be to selectively suppress a p53-dependent ''mitotic catastrophe'' response during meiosis and that MAGE genes may represent mammalian equivalents of the germ line apoptosis genes involved in the maintenance of genomic stability and fertility in male germ cells.
Unlike developing male germ cells, normal human cutaneous mast cells and melanocytes do not express MAGE proteins (Jungbluth et al., 2000) . The reason for this is not clear but it probably involves cell-specific transcription factors since demethylation of normal cultured human melanocytes does not cause MAGE gene expression (Karpf et al., 2004) . As alternative KIT signaling pathways involving MiTF and BCL2 are available to promote survival, it appears that the MAGE pathway is not required by normal cutaneous mast cells and melanocytes.
Epigenetic inheritance is a reversible heritable change in gene function or other cell phenotype that occurs without a change in the DNA sequence. Promoter region methylation can be passed on from one generation of a cell to the next and is a major mechanism of epigenetic control of gene expression. It is known that MAGE gene expression is primarily repressed epigenetically by promoter region methylation and that MAGE genes are unusual because they are heavily methylated in all normal tissues except the testes. KIT activation is probably not required for MAGE gene expression in most tumors, as the global demethylation that often occurs with tumor progression may cause demethylation of MAGE promoters independent of KIT expression (De Smet et al., 1999) . However, our data show that KIT activation can prevent MAGE gene promoter region methylation in the proper cellular context and our studies establish a mechanism for tissue-specific regulation of MAGE gene expression. Further delineation of this mechanism will be important, and work published by Tsai et al. (2006) while this paper was under revision offers a clue to potential components of this pathway. These investigators found that DNA methyltransferase-1 activation by the Epstein-Barr virus protein LMP1 required functional June-terminal kinase (JNK). Because JNK is a downstream mediator of KIT, JNK is an attractive target for additional study.
It has long been recognized that the limited tissue distribution of MAGE proteins provides an opportunity for tumor-specific treatment of many different malignancies (Strohmeyer et al., 1995; Coulie et al., 2002) , and accumulating data suggest that aberrant expression of MAGE protein may allow malignant cells to stave off mitotic catastrophe induced by abnormal replication or cytotoxic agents. Understanding how MAGE protein expression can be controlled will allow more sophisticated strategies for treatment of MAGE-positive melanomas and other malignancies.
MATERIALS AND METHODS
Reagents, buffers, and cells
Iscove's media for cell culture was purchased from Cellgro (Midatech Inc, Herndon, VA). Trizol reagent and SuperScript choice system were from Invitrogen (Grand Island, NY). Pheno/chloroform/ isoamyl alcohol was from Ambion (Austin, TX). Rneasy Minikit was from Qiagen Inc. (Valencia, CA). RNA Transcript labeling Kit was from Enzo Diagnostics (Farmingdale, NY). Affymetrix HU133A genechips were purchased from Affymetrix (Santa Clara, CA).
Two subclones of the human mast cell leukemia line HMC1 were used for this study. The HMC1.1 subclone expresses a valine to glycine substitution in codon 560 (Val560Gly) of the KIT intracellular juxtamembrane region. The HMC1.2, subclone expresses the Val560Gly mutation and a second substitution, aspartate to valine in codon 816 (Asp816Val) in the kinase enzymatic site. Cells were grown in Iscove supplied with 10% heat-inactivated fetal bovine serum, 0.01% monothioglycerol at 371C under 5% CO 2 in a humidified atmosphere.
Treatment of HMC1 cells with Imatinib
The dose and incubation times were pretested to ensure that KIT activity in HMC1.1 cells was completely inhibited (data not shown). Imatinib (Novartis, New York, NY) or phosphatebuffered saline was added directly to 2 Â 10 7 HMC1 cells and incubated for 4 hours. A total of 5 Â 10 6 cells were used for Western blot analysis, and RNA was isolated from the rest for microarray analysis.
Microarray probe preparation
Total RNA was extracted using Trizol reagent and cleaned with the Rneasy Mini Kit according to the manufacturer's instructions. Briefly, 10 mg of total RNA was reverse-transcribed into double-stranded cDNA using a (deoxythymidine)-24 primer containing a T7 polymerase promoter (Genet, La Jolla, CA). cDNA was purified and used for in vitro transcription in the presence of biotinylated UTP and CTP using the BioArray high-yield RNA transcript labeling Kit. Biotinylated cRNA was purified and qualified by agarose gel and spectrophotometery (260 nM/280 nMX1.8). The cRNAs were then heat-fragmentated at 941C for 35 minutes and stored at À201C until hybridization.
Hybridization and scan
Fifteen micrograms of fragmentated, biotinlytaed cRNA were hybridized with the affymetrix arrays at 451C for 16 hours, and then washed and stained by using the Genechip Fluidics station. The arrays were scanned with the GeneArray scanner (Affymetrix), and the fluorescence images obtained were processed by the expression analysis algorithm in Affymetrix Microarray Suite (MAS), version 5.0.
Data analysis
MAS.CEL. files were converted into .DCP files using dCHIP (http:// www.dchip.org), as described previously by Li and Wong (Genome Biol 2001, 2:RESEARCHH0032). The DCP files were normalized, and raw gene expression data were generated using the dCHIP system of model-based analysis. For comparison of gene expression profiles between Imatinib-treated and control HMC1.1 cells, a twopronged strategy was used. The first comparison was performed using dCHIP software itself, where the control cells were designated as baseline, and the Imatinib-treated cells were designated as experiment; three independent replicates were used. Genes altered over 1 (or 2)-fold in the Imatinib-treated versus control groups were then identified by defining the appropriate filtering criteria in the dCHIP software (mean E(Imatinib treated cells)/mean B (control cells) 41-or 2-fold; mean EÀmean B4100, Po0.05, t-test). We first chose a low onefold threshold to get the global gene expression patterns induced by Imatinib, and twofold change to get specifically regulated genes. A second comparison was performed using RBioconductor. Genes in the intersection of the two methods of data analysis were considered as potential molecular targets of Imatinib. Hierarchical clustering of gene expression profiles was performed using Pearson's correlation with a threshold of Po0.005 for significant clusters. For hierarchical clustering of experimental samples, Pearson's correlation was used at a threshold of Po0.05 for significant clusters. Finally, visual inspection of microarray data was used to search for genes relevant to KIT, mast cell, or melanocyte biology which showed significant change that was below the onefold threshold. The six MAGE genes listed in Table 2 were identified from the intersection of data sets from dCHIP and R-Bioconductor.
Immunoblotting MAGE protein expression was determined by immunoblotting of whole cell lysates using standard techniques. The antibodies we used for MAGE are pan-MAGE-A (monoclonal, Zymed, South San Francisco, CA), anti-MAGE-B2 (polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA), or anti-human MAGE-C2 (monoclonal, kindly supplied by Ludwig Institute for Cancer Research, New York, NY). For KIT phosphorylation, cells lysates were immunoprecipitated with mouse anti-c-KIT monoclonal antibody (Santa Cruz Biotechnology), electrophoresis in polyacrylamide gel with SDS, immunoblotting with antiphosphotyrosin antibody (Upstate, Lake Placid, NY), then stripped and reprobed with anti-c-KIT antibody as described previously (Wischnewski et al., 2006) .
Bisulfite modification
Genomic DNA (1 mg) was denatured in 0.3 M NaOH at 371C for 10 minutes. Sulfonation and de-amination of DNA was performed by incubating for 16 hours at 551C with sodium bisulfite solution (Chemicon, Billerica, MA). Modified DNA was desalted and purified with the Wizard DNA purification kit (Promega, Madison, WI) and desulfonated in 0.3 M NaOH at 371C for 5 minutes. DNA was purified with Wizard DNA purification kit and eluted in 30 ml sterile water and performed methylation-specific PCR (MSP) using specific methylated (M) and unmethylated (U) primers for MAGE-A3 and MAGE-C2.
